首页> 美国卫生研究院文献>World Journal of Cardiology >Changes in the safety paradigm with percutaneous coronary interventions in the modern era: Lessons learned from the ASCERT registry
【2h】

Changes in the safety paradigm with percutaneous coronary interventions in the modern era: Lessons learned from the ASCERT registry

机译:现代时代经皮冠状动脉介入治疗的安全范例的变化:从ASCERT注册中心获得的经验教训

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

In the past, comparative effectiveness trials evaluating percutaneous coronary interventions (PCI), using either balloon angioplasty or bare metal stent (BMS) implantation, versus coronary artery bypass surgery (CABG) found similar survival rates at long-term follow-up with both revascularization strategies. Two major meta-analyses of these trials reported 5- and 6-year comparative effectiveness between PCI and CABG: one included only four trials that compared PCI with BMS implantation versus CABG whereas the largest one also included trials using balloon angioplasty. In these studies, the authors observed no survival differences between groups although a significant survival advantage was seen in diabetics treated with CABG and this benefit was also perceived in elderly patients. In both reports, number of involved vessels, presence of left anterior descending artery stenosis or poor left ventricular ejection fraction were no predictors of poor survival with PCI. Therefore, extent of the coronary artery disease (CAD) was not associated with poor outcome after PCI in the pre-drug eluting stent (DES) era. Recently, the ASCERT (Database Collaboration on the Comparative Effectiveness of Revascularization Strategies) registry found higher mortality rate with PCI in patients ≥ 65 years old in comparison with CABG, and advantages of surgery were seen in all subgroups including those at low risk. In this registry, PCI was accomplished by implantation of the first type of DES designs in 78% of cases. The intriguing observation of high mortality rate with PCI, including for non-diabetics and patients with two-vessel CAD, meaning a lack of clinical benefit with DES implantation, had not been seen previously. The study was not randomized, although its results are largely strengthened by its sample size. In this manuscript, the authors describe other registries and randomized trials reporting similar results supporting the findings of the aforementioned study and explore the reasons for these results, while also searching for potential solutions.
机译:过去,使用球囊血管成形术或裸金属支架(BMS)植入术进行的经皮冠状动脉介入治疗(PCI)与冠状动脉搭桥术(CABG)进行比较的有效性试验发现,两种血管重建术在长期随访中的生存率相似策略。这些试验的两项主要荟萃分析报告了PCI和CABG在5年和6年的比较有效性:一项仅包括将PCI与BMS植入与CABG进行比较的四项试验,而最大的一项也包括使用球囊血管成形术的试验。在这些研究中,作者观察到两组之间没有生存差异,尽管在接受CABG治疗的糖尿病患者中观察到了显着的生存优势,并且在老年患者中也发现了这一优势。在这两个报告中,介入血管的数量,左前降支狭窄的存在或左心室射血分数差均不能预测PCI生存率低。因此,在药物前洗脱支架(DES)时代,PCI后冠状动脉疾病(CAD)的程度与不良预后无关。最近,ASCERT(血运重建策略比较有效性数据库合作)注册中心发现,≥65岁的患者中PCI的死亡率高于CABG,在所有亚组(包括低危人群)中都看到了手术的优势。在该注册表中,通过在78%的病例中植入第一类DES设计来完成PCI。先前从未见过关于PCI的高死亡率的有趣观察,包括非糖尿病患者和两支血管CAD患者,这意味着DES植入缺乏临床益处。尽管该研究的结果在很大程度上被样本量所加强,但该研究并未被随机化。在这份手稿中,作者描述了其他注册管理机构和随机试验,这些试验和试验报告了相似的结果,支持了上述研究的结果,并探讨了产生这些结果的原因,同时还寻找了可能的解决方案。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号